Hmmm, according to your link, Bescreened performed a non-clinical trial on a whopping 110 people in 2017, 45 of whom where known to have colorectal cancer. The question is, what have they been doing these last 6 years?
CSIRO do not take products to market. They have retained a 5% interest in Colostat.
Market cap is market cap
100,000 tests is not very many
Colostat at $100 to the end consumer is still very low cost. FIT is $150 and 60% of them end up being thrown out!
Show me another simple blood test that has been through 7 rigorous Australian trials (I.e. highly regulated), is processed on existing lab infrastructure, is 35% more accurate than FIT, even at early stages, and is low cost with or without overhead costs... oh that's right, Colostat!
In my opinion, commercial partners will be quite keen on this product.
- Forums
- ASX - By Stock
- RHY
- BeScreened
BeScreened, page-2
Featured News
Add RHY (ASX) to my watchlist
(20min delay)
|
|||||
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $28.58M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5969 | 13.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.5¢ | 21297 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5969 | 0.130 |
6 | 126159 | 0.115 |
2 | 7500 | 0.110 |
2 | 55000 | 0.105 |
3 | 120000 | 0.100 |
Price($) | Vol. | No. |
---|---|---|
0.115 | 21297 | 1 |
0.130 | 109978 | 5 |
0.135 | 31506 | 2 |
0.140 | 113086 | 4 |
0.150 | 1038543 | 3 |
Last trade - 16.16pm 15/11/2024 (20 minute delay) ? |
Featured News
RHY (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online